

Noriaki Arakawa

*Member of the WHO International Working Group for Drug Statistics
Methodology*

Biography

Dr Noriaki Arakawa is a Japanese public servant specializing in medicinal safety science and regulatory sciences. In his current role as 1st Section Chief in the Division of Medicinal Safety Science at the National Institute of Health Sciences, he leads a team focused on the development of diagnostic technologies for severe adverse drug reactions such as drug-induced lung injury liver injury, as well as research in the oncology field, particularly related to ovarian and prostate cancers. His work involves the application of proteomics, biochemistry, and molecular cellular biology.

Before his current position, he held multiple academic roles at Yokohama City University, including Assistant Professor in the Department of Medical Life Science from 2005 to 2016 and as a Postdoctoral Researcher at Kyoto Prefectural University of Medicine from 2003 to 2005. He obtained his PhD in Biotechnology from Kansai University in 2003, after completing his MSc and B.S. in the same field at the same institution.

He specialized in proteomics, pharmacogenomics, and biomarker research, with a strong focus on regulatory and medicinal safety sciences. His contributions to the field have been recognized with awards including the Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology in 2022, and the Japanese Society of Human Proteome Organization's Incentive Award in 2014.